{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:47:16Z","timestamp":1788306436803,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005809","name":"Hyderabad Eye Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10792-020-01543-w","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T11:02:50Z","timestamp":1597057370000},"page":"3539-3545","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prospective clinical study of two different treatment regimens of combined laser photocoagulation and intravitreal bevacizumab for retinopathy of prematurity: the Indian Twin Cities ROP Study (ITCROPS) database report number 9"],"prefix":"10.1007","volume":"40","author":[{"given":"Venkateshnaidu","family":"Laveti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Balakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmaja Kumari","family":"Rani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashik","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhadra","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,10]]},"reference":[{"key":"1543_CR1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/IAE.0b013e318169faee","volume":"28","author":"R Axer-Siegel","year":"2008","unstructured":"Axer-Siegel R, Maharshak I, Snir M, Friling R, Ehrlich R, Sherf I, Shalev B, Sirota L, Weinberger D (2008) Diode laser treatment of retinopathy of prematurity: anatomical and refractive outcomes. Retina 28:839\u2013846","journal-title":"Retina"},{"key":"1543_CR2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ajo.2010.10.007","volume":"151","author":"S Jalali","year":"2011","unstructured":"Jalali S, Kesarwani S, Hussain A (2011) Outcomes of a protocol-based management for zone 1 retinopathy of prematurity: the Indian Twin Cities ROP Screening Program report number 2. Am Jl Ophthalmol 151:719\u2013724","journal-title":"Am Jl Ophthalmol"},{"key":"1543_CR3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4103\/0301-4738.71689","volume":"58","author":"S Jalali","year":"2010","unstructured":"Jalali S, Azad R, Trehan HS, Dogra MR, Gopal L, Narendran V (2010) Technical aspects of laser treatment for acute retinopathy of prematurity under topical anesthesia. Ind Jl Ophthalmol 58:509\u2013515","journal-title":"Ind Jl Ophthalmol"},{"key":"1543_CR4","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684\u20131694","journal-title":"Arch Ophthalmol"},{"key":"1543_CR5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Eng J Med 364:603\u2013615","journal-title":"N Eng J Med"},{"key":"1543_CR6","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00417-010-1375-0","volume":"248","author":"JY Lee","year":"2010","unstructured":"Lee JY, Chae JB, Yang SJ, Yoon YH, Kim JG (2010) Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefe's Arch Clin Exp Ophthalmol 248:1257\u20131262","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"key":"1543_CR7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4103\/0974-9233.65500","volume":"17","author":"AE Ahmed","year":"2010","unstructured":"Ahmed AE, Channa R, Durrani J, Ali A, Ahmad K (2010) Early experience with intravitreal bevacizumab combined with laser treatment for retinopathy of prematurity. Mid East Afr Jl Ophthalmol 17:264\u2013267","journal-title":"Mid East Afr Jl Ophthalmol"},{"key":"1543_CR8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/IAE.0b013e318296e26d","volume":"34","author":"J Kim","year":"2014","unstructured":"Kim J, Kim SJ, Chang YS, Park WS (2014) Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity. Retina 34:77\u201382","journal-title":"Retina"},{"key":"1543_CR9","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","volume":"28","author":"GA Lalwani","year":"2008","unstructured":"Lalwani GA, Berrocal AM, Murray TG, Buch M, Cardone S, Hess D, Johnson RA, Puliafito CA (2008) Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 28:S13\u201318","journal-title":"Retina"},{"key":"1543_CR10","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","volume":"245","author":"EJ Chung","year":"2007","unstructured":"Chung EJ, Kim JH, Ahn HS, Koh HJ (2007) Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefe's Arch Clin Exp Ophthalmol 245:1727\u20131730","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"key":"1543_CR11","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"103","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R (2012) Reactivation of retinopathy of prematurity after intravitreal bevacizumab. Arch Ophthalmol 103:1000\u20131006","journal-title":"Arch Ophthalmol"},{"key":"1543_CR12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10792-013-9843-2","volume":"34","author":"VP Dave","year":"2014","unstructured":"Dave VP, Jalali S, Rani PK, Padhi TR (2014) Characteristics and outcomes of anterior hyaloidal fibrovascular proliferation in lasered retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Study (ITCROPS) report number 4. Int Ophthalmol 34:511\u2013517","journal-title":"Int Ophthalmol"},{"key":"1543_CR13","first-page":"77","volume":"52","author":"MA Klufas","year":"2015","unstructured":"Klufas MA, Chan RV (2015) Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years. JAAPOS 52:77\u201384","journal-title":"JAAPOS"},{"key":"1543_CR14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/08820538.2013.835842","volume":"29","author":"J Chhablani","year":"2014","unstructured":"Chhablani J, Rani PK, Balakrishnan D, Jalali S (2014) Unusual adverse choroidal reaction to intravitreal bevacizumab in aggressive posterior retinopathy of prematurity: the Indian Twin Cities ROP screening (ITCROPS) data base report number 7. Semin Ophthalmol 29:222\u2013225","journal-title":"Semin Ophthalmol"},{"key":"1543_CR15","doi-asserted-by":"crossref","first-page":"F327","DOI":"10.1136\/archdischild-2012-302365","volume":"98","author":"S Jalali","year":"2013","unstructured":"Jalali S, Balakrishnan D, Zeynalova Z, Padhi TR, Rani PK (2013) Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening database Report number 5. Arch Dis Child Fetal Neonatal Ed 98:F327\u2013F333","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"1543_CR16","unstructured":"Jalali S, Laveti V, Balakrishnana D, Rani PK, Mohamed A (2018) Prospective clinical study of two different regimens of combined laser photocoagulation and intravitreal bevacizumab treatment for retinopathy of prematurity. In: Hot topics in ROP meet, Chicago. https:\/\/pdfs.semanticscholar.org\/2e33\/db395c1fe823b73cf54a69cbf9f18757d9ae.pdf Meeting abstract 68"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-020-01543-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-020-01543-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-020-01543-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T23:10:30Z","timestamp":1628550630000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-020-01543-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1543"],"URL":"https:\/\/doi.org\/10.1007\/s10792-020-01543-w","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,10]]},"assertion":[{"value":"22 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study had Institutional Ethics Committee approval (Ethics Ref. No. LEC 06-14-053) including the off-label use of bevacizumab for ROP.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent for each case was obtained from the parent or legal guardian of the baby.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}